Application value of ATP based bioluminescence tumor chemosensitivity assay in the chemotherapy for hydrothorax caused by non-small cell lung cancer

• Published in: The Chinese-German journal of clinical oncology Vol. 12; no. 5; pp. 210 - 212
• Main Authors: Le, Kaijian, Jia, Yuming, Wang, Jing, Jiang, Maoqiong
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.05.2013; Department of Oncology, The No. 2 People's Hospital of Yibin, Yibin 644000, China
• Subjects: ATP; Cancer Research; Medicine; Medicine & Public Health; Oncology; Surgical Oncology; 临床应用; 价值; 化疗药物; 肿瘤; 胸水; 药敏试验; 非小细胞肺癌; ATP based bioluminescence tumor chemosensitivity assay (ATP-TCA); hydrothorax; non-small cell lung cancer (NSCLC)
• ISSN: 1610-1979; 1613-9089
• DOI: 10.1007/s10330-013-1153-7

Objective： The aim of the study was to investigate the clinical value and application of ATP based bioluminescence tumor chemosensitivity assay （ATP-TCA） in the chemotherapy for hydrothorax caused by non-small cell lung cancer （NSCLC）. Methods： Hydrothorax specimens from 120 NSCLC patients were analyzed by ATP-TCA and the most sensitive chemotherapeutic drugs were used in NSCLC patients （treatment group）. At the same time, 56 NSCLC patients with hydrethorax were admitted in our Hospital （Department of Oncology, The No. 2 People＇s Hospital of Yibin, China） and given chemotherapy without guidance of the ATP-TCA （control group）. Before the third chemotherapeutic cycle, clinical outcomes were analyzed in the two groups. Results： Effective rate of hydrothorax in treatment group was 67%, while 46% in control group （P 〈 0.05）. In refractory hydrothorax patients, they were 69% and 40% （P 〈 0.05）, respectively.In vitro results correlated well with clinical outcomes （P 〈 0.01）. Conclusion： Effective rate of chemotherapy for hydrothorax in NSCLC is higher in treatment group than that in control group. ATP-TCA is especially helpful for refractory hydrothorax.